Abemaciclib, aromataza inhibitori, Eli Lilly va Kompaniya, endokrin terapiya, Tamoksifen, Verzenio
Endokrin terapiyasi bilan Abemaciclib HER 2 ijobiy ko'krak saratonida FDA tomonidan tasdiqlangan
2023 yil mart: Abemaciclib (Verzenio, Eli Lilly and Company) va endokrin terapiya (tamoksifen yoki aromataz inhibitori) oziq-ovqat va farmatsevtika idorasi (FDA) tomonidan kattalardagi bemorlarni adjuvant davolash uchun tasdiqlangan.
CAR T Hujayra terapiyasi sinovlari, Glioblastoma, glioblastoma sinovlari, glioma
Takroriy glioblastoma uchun anti-B7-H3 CAR-T hujayra terapiyasining xavfsizligi va samaradorligini o'rganish
March 2023: Study Type : Interventional (Clinical Trial)Estimated Enrollment : 30 participantsAllocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: a "3+3" design is used to determine Maximum..
Amerika Gematologiya Jamiyati, Karteyva, Xitoy, JW Therapeutics, relmacabtagene autoleucel
JW Therapeutics 64-ASH yillik yig'ilishida follikulyar limfoma va mantiya hujayrali limfomadagi Carteyva® haqidagi so'nggi klinik ma'lumotlarni taqdim etadi
SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing, and selling cell immunotherapy products. At the 64th American Society ..
dMMR, Dostarlimab, GlaxoSmithKline, Jemperli
Dostarlimab-gxly FDA tomonidan dMMR endometrium saratoni uchun tasdiqlangan
2023-yil, fevral: Dostarlimab-gxly (Jemperli, GlaxoSmithKline MChJ) oldingi kasallik paytida yoki undan keyin rivojlangan, nomutanosiblik tuzatish etishmovchiligi (dMMR) takroriy yoki rivojlangan endometrium saratoni bilan og'rigan katta yoshli bemorlarni davolash uchun FDA ruxsatini oldi.
Daiichi Sankyo, TAQDIR-Ko'krak04, kuchliroq bo'ling, fam-trastuzumab deruxtecan-nxki
Fam-trastuzumab deruxtecan-nxki FDA tomonidan HER2 past ko'krak saratoni uchun tasdiqlangan
2022 yil avgust: Rezektsiya qilinib bo'lmaydigan yoki metastatik HER2-past (IHC 1+ yoki IHC 2+/ISH) ko'krak bezi saratoni bilan og'rigan, metastatik sharoitda oldindan kimyoterapiya olgan yoki olti yoki undan keyin kasallikning qaytalanishini boshdan kechirgan kattalar uchun.
AstraZeneca farmatsevtika, BRCA, gBRCAm, Linparza, olaparib, Olympia
Olaparib yuqori xavfli erta ko'krak saratonini adjuvan davolash uchun tasdiqlangan
2022 yil mart: Oziq-ovqat va farmatsevtika idorasi olaparibni (Lynparza, AstraZeneca Pharmaceuticals, LP) BRCA mutatsiyaga uchragan (gBRCAm) zararli yoki shubhali zararli mikroblari bo'lgan kattalardagi bemorlarni adjuvant davolash uchun tasdiqladi.
Atezolizumab, Bevacizumab, nivolumab, Regorafenib, Stivarga, Tecentriq
Jigar saratonini davolash uchun tasdiqlangan dorilar
2021 yil dekabr: Jigar saratonini davolash uchun quyidagi dorilar tasdiqlangan: Preparatni qabul qilishdan oldin, retsept bo'yicha ma'lumotlarni tekshiring. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-SM..)
FDA, KRAS G12C, Lumakralar, NSCLC, sotorasib
FDA ilgari dorilarga chidamli deb hisoblangan o'pka saratoni mutatsiyasi uchun birinchi maqsadli terapiyani tasdiqladi.
20 yil 2021-avgust: Yaqinda 2021 yil may oyida Lumakras (sotorasib) AQSh oziq-ovqat va farmatsevtika idorasi tomonidan kichik hujayrali bo'lmagan o'pka saratoni bilan og'rigan va hech bo'lmaganda bitta oldingi tizimdan o'tgan bemorlarni davolashning birinchi usuli sifatida tasdiqlangan.
KEYTRUDA, Tashkilot,, NCT02362594, Pembrolizumab, QABUL QILING, USFDA
Pembrolizumab melanomani yordamchi davolash uchun FDA tomonidan tasdiqlangan
On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after full resection. The approval ..
Ablinks, ADAMTS13, KABLIVI, kaplacizumab-yhdp, FDA, immunosupressiv terapiya, USFDA
Caplacizumab-yhdp FDA tomonidan tasdiqlangan
6 yil 2019 fevralda oziq-ovqat va farmatsevtika idorasi plazma almashinuvi va immunosupressiv davo bilan birgalikda trombotsit trombotsitopeni sotib olingan kattalar bemorlari uchun kaplacizumab-yhdp (CABLIVI, Ablynx NV) ni tasdiqladi.